| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Laboratory of Prion Diseases, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan
2 Department of Pathobiological Science, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro 080-8555, Japan
Correspondence
Motohiro Horiuchi
horiuchi{at}vetmed.hokudai.ac.jp
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Present address: Foreign Animal Disease Division, Animal Disease Control Department, National Veterinary Research and Quarantine Service, 480 Anyang-6 dong, Manan-gu, Anyang 430-824, Republic of Korea. 
Present address: Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Many compounds or strategies have been reported to inhibit PrPSc formation, including polyanions, glycosaminoglycans, phosphorothioate oligonucleotides, tetrapyrroles, polyene antibiotics, tricyclic compounds, PrP peptides, dominant-negative PrP, cysteine protease inhibitors, PrP immunization and small interfering RNAs (reviewed by Trevitt & Collinge, 2006
). Most of these compounds and treatments antagonize PrPSc formation in cells persistently infected with prions. However, the anti-prion effects in vivo are not always consistent with those observed in vitro. Indeed, some of the compounds and treatments protect animals from experimental inoculation with prions or delay the onset of disease when administered before, simultaneously or soon after inoculation with prions via a peripheral route (Ehlers & Diringer, 1984; Farquhar & Dickinson, 1986; Ladogana et al., 1992; Priola et al., 2000). In addition, only a few compounds, such as amphotericin B, its derivative, MS-8209 and pentosan polysulfate (PPS), can prolong survival of mice infected with prions even when administered in the middle or late stage of prion infection via intracerebral inoculation (Demaimay et al., 1997; Doh-ura et al., 2004). Because intraventricular infusion of PPS at a late stage prolongs the incubation period of the disease in transgenic mice that overexpress PrP (Doh-ura et al., 2004), clinical trials using PPS to treat human prion diseases are moving forward (Todd et al., 2005). The current evidence suggests that PPS treatment of vCJD patients appears to have some beneficial effects, although the specificity of the effects still needs to be evaluated carefully (Rainov et al., 2007).
Anti-PrP antibodies prevent direct interaction between PrPC and PrPSc in a cell-free conversion reaction (Kaneko et al., 1995; Horiuchi & Caughey, 1999). Subsequent reports have shown that anti-PrP antibodies prevent prion propagation in cells persistently infected with prion (Enari et al., 2001; Peretz et al., 2001; Gilch et al., 2003; Kim et al., 2004b; Perrier et al., 2004; Feraudet et al., 2005). The inhibitory effect of anti-PrP antibodies has also been demonstrated in vivo. Transgenic mice expressing monoclonal antibody (mAb) 6H4 were shown to be resistant to prion infection via the intraperitoneal route (Heppner et al., 2001). Moreover, active immunization with recombinant PrP, synthetic PrP peptide or a DNA vaccine has been shown to delay the onset of the disease in mice following peripheral prion infection, although immunization was a prerequisite to obtain the prophylactic effect (Sigurdsson et al., 2002; Schwarz et al., 2003; Goñi et al., 2005; Fernandez-Borges et al., 2006). Passive immunization with anti-PrP antibodies was found to be effective in preventing prion infection via the peripheral route if antibodies were administered shortly after prion inoculation, but was not following intracerebral prion infection or if administered on or after clinical onset following intraperitoneal prion infection (White et al., 2003). These results suggest that anti-PrP antibodies can protect against establishment of prion infection in peripheral tissues and thus may be useful for post-exposure prophylaxis. However, the therapeutic potential of anti-PrP antibodies, including whether or not anti-PrP antibodies antagonize prion propagation in the brain and can inhibit disease progression when applied after clinical onset, remains to be elucidated.
To evaluate the therapeutic effects of anti-PrP antibodies on prion diseases more precisely, we carried out intraventricular infusion of anti-PrP mAbs in mice that had been inoculated intracerebrally with prions. Here, we show that intraventricular infusion of anti-PrP mAbs reduced the level of accumulation of PrPSc and reduced spongiform changes and gliosis relative to negative controls. Furthermore, we observed prolongation of the incubation time in mice infected with the Chandler strain, even when infusion was initiated at the time of clinical onset of the disease.
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). Anti-feline parvovirus mAb P2-284 (IgG1) was used as a negative control (Horiuchi et al., 1997). The mAbs were dialysed for 3 days against PBS prior to intraventricular infusion. An Alexa Fluor 488 Protein Labelling kit (Molecular Probes) was used for fluorescent labelling of mAbs.
The following rabbit polyclonal antibodies were used as primary antibodies for immunohistochemistry: B103, which recognizes bovine PrP synthetic peptide aa 103–121 (Horiuchi et al., 1995), anti-glial fibrillary acidic protein (GFAP; Dako) to visualize astrocytes and anti-Iba1 (Wako) to visualize microglia.
Mice and prion strains.
All procedures for animal experiments were carried out according to protocols approved by the Institutional Committee for Animal Experiments. Mouse-adapted scrapie strains Obihiro and Chandler were used in this study. For intracerebral inoculation, 4-week-old female ICR mice were purchased from CLEA Japan. Twenty microlitres of 10 % brain homogenate from mice infected with the Obihiro or Chandler strain was injected into the left hemisphere. Twelve-week-old female ICR mice were used to determine the distribution of mAbs and to analyse neuronal toxicity by anti-PrP mAbs.
Intraventricular infusion of mAbs using an osmotic pump.
Alzet Mini-Osmotic Pumps, models 2001, 2002 and 2004 (DURECT), were used in this study. Filling of the osmotic pumps with antibody solution was carried out according to the manufacturer's instructions. The pre-filled pumps were then placed in PBS at 37 °C for 24 h. Mice were fitted with a stainless steel cannula supplied with the Alzet Brain Infusion kit (DURECT) and positioned according to stereotaxic coordinates into the left lateral ventricle of the brain (bregma – caudal 1.0 mm, lateral 1.0 mm with a depth of 3 mm below the dura). The osmotic pumps were subsequently implanted subcutaneously into the back and connected to the fitted cannula. All surgical procedures were performed under anaesthesia by intramuscular injection of xylazine (10 mg kg–1) and ketamine (50 mg kg–1). After surgery, cefotaxime (Chugai) was administered subcutaneously (40 mg kg–1) and a gentamicin ointment (Schering-Plough) was pasted on the suture line for 3 days. All mice were housed individually during post-surgery observation periods. Mice that died within a few days of the operation were excluded from the statistical analysis.
Stereotaxic injection of mAbs.
Mice were anaesthetized as described above and placed onto a stereotaxic apparatus (Narishige). A linear scalp incision was made and the skull was exposed. Bilateral burr holes were drilled to accommodate stereotaxic placement into the left and right hippocampus (bregma – caudal 2.0 mm, lateral 2.1 mm). Using a Hamilton syringe with a 31-gauge needle, 2 µl mAbs (2 mg ml–1) were injected into the left and right hippocampus, respectively, at a depth of 2 mm below the dura. Injection was carried out over a period of 15 min.
Western blotting.
Brains were sagittally hemi-sectioned and homogenized in 10 % (w/v) TMS buffer [50 mM Tris/HCl (pH 7.5), 5 mM MgCl2, 5 % glucose]. To detect PrPSc, 200 µl brain homogenate was mixed with an equal volume of a detergent buffer [8 % Zwittergent 3-14, 1 % Sarkosyl, 100 mM NaCl, 50 mM Tris/HCl (pH 7.5)] and treated with collagenase (0.5 mg ml–1) for 15 min at 37 °C. The samples were then digested with proteinase K (PK; Roche) at 20 µg ml–1 for 30 min at 37 °C. After terminating PK activity by adding Pefabloc (Roche) at 2 mM, samples were treated with 40 µg DNase I ml–1 for 5 min. A half volume of a mixture of 2-butanol and methanol (5 : 1) was added and the PrPSc was pelleted by centrifugation at 20 000 g for 10 min at 20 °C. The resulting pellet was dissolved in 1x SDS sample buffer [62.5 mM Tris/HCl (pH 6.8), 5 % glycerol, 3 mM EDTA, 4 % β-mercapthoethanol, 0.04 % bromophenol blue, 5 % SDS, 4 M urea] by boiling for 5 min. SDS-PAGE and Western blotting were carried out as described elsewhere (Uryu et al., 2007)
Histopathology and immunohistochemistry.
Mouse brains that had been infused with Alexa Fluor 488-conjugated mAbs were frozen in Tissue-Tek OCT compound (Sakura) and cryosections of 16–20 µm were prepared. The sections were dried and fixed with acetone for 10 min. Sections were mounted with Vectashield containing propidium iodine (PI; Vector Laboratories) and examined with a Nikon C1 laser confocal microscope. The presence of infused mAb was also confirmed by direct detection as follows. The sections were reacted with EnVision+ System-labelled polymer conjugated to horseradish peroxidase (HRP) (Dako) for 45 min at 37 °C and positive signals were detected using Simple Stain 3,3'-diaminobenzidine (DAB) solution (Nichirei). This was followed by counterstaining with Mayer's haematoxylin (Wako).
Dissected mouse brains were fixed in 10 % formalin and embedded in paraffin. Sections (4 µm) were deparaffinized, rehydrated and subjected to haematoxylin and eosin (H&E) staining or immunohistochemistry. Antigen retrieval for immunohistochemistry was performed by hydrolytic autoclaving at 135 °C for 20 min for detection of PrPSc and at 121 °C for 10 min for GFAP and Iba1 (Furuoka et al., 2005). The sections were treated with 3 % H2O2 for 5 min, blocked with 10 % normal goat serum for 30 min and then incubated for 45 min at 37 °C with B103 at a dilution of 1 : 100, anti-GFAP at 1 : 5000 or anti-Iba1 at 1 : 100. After washing with PBS, the sections were reacted with EnVision+ System-labelled polymer–HRP for 45 min at 37 °C. The sections were then rinsed and developed with Simple Stain DAB, followed by counterstaining with Mayer's haematoxylin.
Terminal uridine deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining.
Neuronal cell death was examined using an In situ Cell Death Detection kit (Roche). Four micrometer sections of paraffin-embedded brain tissue were deparaffinized, rehydrated and incubated with 10 µg PK ml–1 for 10 min at 37 °C. After washing with PBS, the sections were incubated with labelling mixture containing terminal deoxynucleotidyl transferase and digoxigenin-labelled dUTP-conjugated FITC for 60 min at 37 °C. The sections were counterstained with PI and examined with a C1 laser confocal microscope.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
were prepared. Fig. 1(c) shows the detection of Alexa Fluor 488-conjugated mAb 31C6 in the hippocampus. Fluorescence was detected over the hippocampus (up to 14 days). Although the area of distribution gradually narrowed thereafter, mAbs were still detectable in the hippocampus at 20 days after the termination of infusion (i.e. at 34 days). In contrast, a very low-level fluorescent signal was detected in the hippocampus of a mouse infused with Alexa Fluor 488-conjugated mAb P2-284, even at 7 days after the initiation of infusion. These results suggested that the longer duration of mAb 31C6 in the hippocampus compared with the control mAb was due to binding of mAb 31C6 to PrPC.
|
summarizes the distribution of the anti-PrP mAb. The mAb was well distributed to areas surrounding the lateral and dorsal third ventricles, hippocampus and thalamus. The mAb was also detected in areas close to the ventral third ventricles. In addition, mAb was detected in regions of the medulla oblongata that face the fourth ventricle and the subarachnoid space, suggesting that the mAb infused into the lateral ventricle was distributed to many parts of brain, presumably via the flow of cerebrospinal fluid. Although the mAb was distributed to parts of the brain parenchyma, distribution of mAb into the cortex and cerebellum appeared to be less efficient. When observing sections under a microscope, we noticed that the mAb-infused hemisphere showed higher fluorescence intensity than that observed in the contralateral side (data not shown), suggesting that the distribution of mAb was not symmetrical. This tendency was confirmed by direct detection of Alexa Fluor 488-conjugated mAb 31C6 (Fig. 1b).
Effects of anti-PrP mAbs on PrPSc accumulation in the brain
Mice inoculated with Obihiro or Chandler strain reach the terminal stage of the disease at around 150 days post-inoculation (p.i.). Early clinical signs such as ataxia of hind limbs and changes in pelage and posture appear at around 120 days p.i. To evaluate the therapeutic potential of anti-PrP mAbs in a late stage of the disease, infusion of mAbs was started at 120 days p.i. and accumulation of PrPSc and neurohistopathological lesions were analysed.
Fig. 2(a) shows PrPSc accumulation in the brains of mice infected with the Obihiro strain at 30 days post-infusion (150 days p.i.). The mean PrPSc levels in mice treated with mAbs 110, 31C6 and 44B1 were 78, 69 and 77 %, respectively, compared with the control (mAb P2-284; n=2). To determine whether the relative reduction in PrPSc levels was caused by acceleration of PrPSc degradation or deceleration of PrPSc accumulation, we analysed the kinetics of PrPSc accumulation during the period from 127 to 150 days p.i. (Fig. 2b). There was no difference in PrPSc levels in mice treated with anti-PrP mAbs compared with those treated with the negative-control mAb at 127 days p.i. (7 days after the initiation of infusion). However, PrPSc levels increased 2.3-fold in mice treated with the control mAb over the period 127–150 days p.i., whereas PrPSc levels increased only 1.6-, 1.3- and 1.3-fold in mice treated with mAbs 110, 31C6 and 44B1, respectively. These results indicated that anti-PrP mAbs can reduce the rate of PrPSc accumulation in the brain, even when treatment is initiated at a late stage of the disease.
|
(at 150 days p.i.) were examined histopathologically. Although mAbs were more readily detected in the infused side than in the contralateral side (Fig. 1), spongiform changes in the hippocampus and thalamus of mice treated with mAbs 110, 31C6 and 44B1 were nevertheless milder than those treated with the negative-control mAb (Fig. 2c).
Immunohistochemical examination also revealed that anti-PrP mAbs affected the progression of neuropathological lesions in mice infected with the Obihiro strain (Fig. 3). Consistent with the reduction in PrPSc levels by anti-PrP mAbs (Fig. 2a), PrPSc deposition in the hippocampus and thalamus of mice infused with mAbs 110 and 31C6 was milder than in the negative control. In addition, astrogliosis (as evaluated by GFAP staining) appeared to be reduced in mice treated with anti-PrP mAbs compared with the negative control. Microglial activation in the hippocampus (as detected with anti-Iba1 antibodies) was also reduced in the presence of anti-PrP mAbs; in contrast, the effect was marginal in the thalamus.
|
). However, the effect of anti-PrP mAb on gliosis appeared to differ for the two different prion strains. Anti-PrP mAbs apparently reduced astrogliosis in the hippocampus and thalamus of mice infected with the Obihiro strain (Fig. 3), but only a slight reduction in astrogliosis was observed for mice infected with the Chandler strain (Fig. 4). Moreover, although microglial activation in the thalamus of mice infected with the Obihiro strain was slightly reduced by treatment with anti-PrP mAbs, it was obviously reduced relative to controls by treatment with mAb 31C6 in mice infected with the Chandler strain (Fig. 4). However, microglial activation as a whole appeared to be moderate in mice infected with the Chandler strain compared with the Obihiro strain; thus, the difference observed could be due to a difference in the level of activation of the microglia between mice infected with the two prion strains.
|
and Table 1). In contrast, for mice infected with the Chandler strain, prolongation of survival was observed in all three groups: infusion initiated at 60, 90 or 120 days p.i. prolonged survival by approximately 10, 13 or 12 days, respectively. Brain sections (H&E stained) of all mice were examined for possible causes of death other than prion disease. Of 96 mice tested, two had severe abscesses around the infused area and thus were excluded from the experimental group.
|
|
). In contrast, no difference was observed for mice infected with the Obihiro strain when mAb infusion was started at 90 or 120 days p.i.
|
), we assessed the neurotoxicity of the mAbs used in this study. First, mAbs were infused into the lateral ventricle for 7 days using an Alzet Mini-Osmotic Pump model 2001 (mAb concentration 1 mg ml–1, pumping rate 1 µl h–1, duration 7 days, volume 200 µl); however, no difference was observed between mice treated with anti-PrP mAbs and those treated with the negative-control mAb (data not shown). To assess neurotoxicity directly, we next stereotaxically injected anti-PrP mAbs and the control mAb into the left and right hippocampus, respectively. The distribution of mAb in the hippocampus was confirmed by injecting Alexa Fluor 488-conjugated mAb 31C6 (Fig. 7a). Although mAb was well-distributed throughout the entire hippocampus on the injected side, TUNEL-positive cells were only detected in a limited area of the pyramidal layer and this was observed even in the right side (the side injected with the control mAb P2-284). Indeed, the TUNEL-positive cells were close to the injection site, suggesting that the TUNEL-positive cells resulted from the trauma of mAb injection. It was interesting that mAbs 106 and 110 recognizing the region adjacent to aa 95–105 did not induce apparent neuronal death.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
and 3). The effect of anti-PrP mAbs appeared to be mainly due to deceleration of PrPSc formation rather than active degradation of PrPSc. Several reports have suggested that binding of anti-PrP antibodies to the first 
-helical domain of PrPC (aa 143–155), which is proposed to be important for the PrPC–PrPSc interaction (Morrissey & Shakhnovich, 1999; Speare et al., 2003), prevents PrPSc formation by inhibiting the direct interaction between PrPC and PrPSc (Enari et al., 2001; Peretz et al., 2001). It has also been suggested that a perturbation of the usual PrPC trafficking by binding of the antibody to PrPC on the cell surface, e.g. sequestration of PrPC on the cell membrane, may be one of the mechanisms of inhibition (Kim et al., 2004b; Feraudet et al., 2005). Consistent with our previous observations (Kim et al., 2004b), mAbs directed against the C-terminal domain (mAb 44B1) and the octapeptide repeat in the N-terminal region (mAb 110), as well as one directed against the first -helix (mAb 31C6), antagonized PrPSc formation in the mouse brain (Fig. 2). Indeed, anti-PrP mAb infused into the lateral ventricle was still detectable in the hippocampus at 20 days after the termination of infusion, whereas only a low level of the negative-control mAb was detected in the same region, even during infusion (Fig. 1). These results suggest that the antibody–PrPC complex remains in the brain parenchyma and therefore that sequestration of PrPC by the antibody is implicated in the inhibition of PrPSc formation in vivo.
Intraventricular infusion of anti-PrP mAbs at a late stage of infection (initiated at 120 days p.i.) reduced levels not only of PrPSc accumulation but also of microglial activation, astrogliosis and spongiform changes. Comparison of neurohistopathological changes observed at 127 versus 150 days p.i. in mice treated with anti-PrP mAbs and the negative-control mAb revealed an apparent reduction in gliosis observed at 150 days p.i., which may be due to a slowdown in the progression of gliosis (data not shown). Although the severity of microglial activation and astrogliosis differed in animals infected with the two different prion strains, the reduction observed was in accordance with the mAb distribution, and the levels of microglial activation and astrogliosis in the hippocampus and thalamus of mice infused with anti-PrP mAbs appeared to be milder than those observed in mice infused with the negative-control mAb. In contrast, no apparent reduction in microglial activation or astrogliosis by anti-PrP mAb was observed in the lateral cortex, where delivery of mAbs appeared to be inefficient (data not shown). It has been reported that the process of conversion of PrPC to PrPSc on neurons rather than extracellular deposition of PrPSc is involved in neuronal degeneration (Brandner et al., 1996; Mallucci et al., 2003; Chesebro et al., 2005). Although the mechanism by which PrPSc formation provokes microglial activation and astrogliosis remains to be elucidated, these results imply that arresting conversion of PrPC to PrPSc via mAb infusion may contribute, at least to some extent, to the observed reduction in microglial activation and astrogliosis.
Previous results have shown that passive immunization with anti-PrP mAb via intraperitoneal injection does not have a protective effect after invasion of prion into the CNS or inoculation of prion via the intracerebral route (White et al., 2003). In contrast, intraventricular infusion of anti-PrP mAb prolonged survival when mAb was infused at the time that PrPSc became detectable in the CNS (e.g. at 60 days p.i.). The difference seems to be explained by inadequate transfer of anti-PrP mAbs into the CNS across the blood–brain barrier when mAbs are administered peripherally. Several compounds, including amphotericin B, PPS, porphyrin derivatives and GN8, have been reported to prolong the survival of mice infected with prion when administered at the middle or late stage of infection, but the animals were still prior to clinical onset (Demaimay et al., 1997; Doh-ura et al., 2004; Kocisko et al., 2006; Kuwata et al., 2007). To the best of our knowledge, there has been only one report of a treatment that prolongs survival of animals already in the clinical phase. Specifically, intraperitoneal administration of MS-8209 was shown to prolong survival of mice infected with the C506M3 strain when treatment was carried out at the time of the appearance of neurological symptoms (Demaimay et al., 1997). Human prion diseases are usually detected after clinical onset and thus the availability of treatments that are effective even after symptoms have begun to appear is highly important. Therefore, it is of interest that intraventricular infusion of anti-PrP mAb was effective for prolongation of survival, even when treatment was initiated after the appearance of early clinical signs (at 120 days p.i.) in mice infected with the Chandler strain. Although in this study mAb infusion for 14 days of duration achieved only 8 % prolongation, the result should encourage further trials with mAbs that may be useful in the development of therapeutic treatment for prion diseases. For instance, continuing treatment over a longer duration, which may keep the effective concentration of mAbs in the brain higher over a longer period of time, may improve the effect on survival. In addition, anti-PrP mAb prolonged survival, despite the fact that the infused mAb was not evenly distributed in the brain but rather was primarily restricted to the hippocampus and thalamus. Thus, it is conceivable that improved delivery of mAb might enhance the effects of anti-PrP mAb on survival. Fab and single-chain antibody fragments have also been shown to inhibit PrPSc formation (Peretz et al., 2001; Donofrio et al., 2005), and the smaller size of these fragments may be beneficial for efficient delivery in tissues.
Although mice infected with either the Obihiro or Chandler strain succumbed to the disease at around 150 days p.i., the effect of mAb infusion on survival differed when administered to mice challenged with different prion strains. For example, mAb infusion of mice infected with the Chandler strain was effective when the mAb was administered at any of the three time points tested (60, 90 and 120 days p.i.), whereas no prolongation was observed in mice infected with the Obihiro strain when mAb infusion was initiated at 90 or 120 days p.i. (Fig. 6). At present, we do not have a precise explanation for this but can speculate on what might explain the difference. First, microglial activation in mice infected with the Obihiro strain was more severe than that in mice infected with the Chandler strain (Figs 3 and 4). Similar to the mouse model for Alzheimer's disease (El Khoury et al., 2007), microglial recruitment is expected to have a protective role in prion disease; however, activated microglia also have neurotoxic effects via production of cytokines, chemokines and reactive oxygen species (Bate et al., 2001, 2002; Marella et al., 2005). Thus, even when mitigated by anti-PrP mAb, the severe microglial activation in mice infected with Obihiro strain may be sufficient for progression of the disease. Secondly, differences in the distribution of PrPSc may account for the differences in the effect of anti-PrP mAb in one prion strain versus the other. For instance, PrPSc accumulation in the hypothalamus of mice infected with the Obihiro strain was more severe than that in mice infected with the Chandler strain (data not shown). Moreover, PrPSc formation in the hypothalamus might not be inhibited efficiently due to the uneven distribution of mAb in the hypothalamus (Fig. 1). These results may explain in part the lack of prolongation in the Obihiro strain-infected mice infused with mAb at 90 or 120 days p.i.
Immunotherapy has been of interest in the treatment of Alzheimer's disease; however, the fact that immunization of β-amyloid peptide caused meningoencephalitis in some patients in clinical trials warns of the adverse effects of autoimmune reactions in vivo (Check, 2002; Nicoll et al., 2003; Orgogozo et al., 2003). Additionally, cross-linking of PrPC by an anti-PrP mAb that recognizes a specific epitope (aa 95–105) provoked degeneration of hippocampal and cerebellar neurons (Solforosi et al., 2004). These adverse effects of antibodies on the CNS have prompted extreme caution in the use of anti-PrP antibodies, in particular, their introduction into the CNS. However, passive immunization is less likely to initiate an autoimmune reaction (Schenk, 2002; Sadowski & Wisniewski, 2004). In this study, we observed no antibody-induced inflammation by intraventricular infusion. In addition, neuronal death in the hippocampus was not observed, even though mAbs 106 and 110, which recognize the region adjacent to aa 95–105, were injected directly into the hippocampus. Although the potential adverse effects, especially an inflammatory response, should be examined carefully, the fact that anti-PrP mAbs interfered with disease progression, even when administered after clinical onset, is particularly encouraging. Although the effect of anti-PrP mAb differed in prion strains, this implies that the immunotherapy might be effective in certain types of human prion disease, if not all. Therefore, the results of this study should promote further efforts to improve the effect of anti-PrP mAbs, such as the form of the antibody, the route of administration and an efficient way of delivering the antibodies.
|
ACKNOWLEDGEMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Bate, C., Boshuizen, R. S., Langeveld, J. P. & Williams, A. (2002). Temporal and spatial relationship between the death of PrP-damaged neurones and microglial activation. Neuroreport 13, 1695–1700.[CrossRef][Medline]
Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C. & Aguzzi, A. (1996). Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339–343.[CrossRef][Medline]
Check, E. (2002). Nerve inflammation halts trial for Alzheimer's drug. Nature 415, 462[Medline]
Chesebro, B., Race, R. & Kercher, L. (2005). Scrapie pathogenesis in brain and retina: effects of prion protein expression in neurons and astrocytes. J Neurovirol 11, 476–480.[CrossRef][Medline]
Demaimay, R., Adjou, K. T., Beringue, V., Demart, S., Lasmézas, C. I., Deslys, J. P., Seman, M. & Dormont, D. (1997). Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J Virol 71, 9685–9689.
Doh-ura, K., Ishikawa, K., Murakami-Kubo, I., Sasaki, K., Mohri, S., Race, R. & Iwaki, T. (2004). Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78, 4999–5006.
Donofrio, G., Heppner, F. L., Polymenidou, M., Musahl, C. & Aguzzi, A. (2005). Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 79, 8330–8338.
Ehlers, B. & Diringer, H. (1984). Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 65, 1325–1330.
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C. & Luster, A. D. (2007). Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13, 432–438.[CrossRef][Medline]
Enari, M., Flechsig, E. & Weissmann, C. (2001). Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 98, 9295–9299.
Farquhar, C. F. & Dickinson, A. G. (1986). Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 67, 463–473.
Feraudet, C., Morel, N., Simon, S., Volland, H., Frobert, Y., Creminon, C., Vilette, D., Lehmann, S. & Grassi, J. (2005). Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem 280, 11247–11258.
Fernandez-Borges, N., Brun, A., Whitton, J. L., Parra, B., Diaz-San Segundo, F., Salguero, F. J., Torres, J. M. & Rodriguez, F. (2006). DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J Virol 80, 9970–9976.
Furuoka, H., Yabuzoe, A., Horiuchi, M., Tagawa, Y., Yokoyama, T., Yamakawa, Y., Shinagawa, M. & Sata, T. (2005). Effective antigen-retrieval method for immunohistochemical detection of abnormal isoform of prion proteins in animals. Acta Neuropathol 109, 263–271.[CrossRef][Medline]
Gilch, S., Wopfner, F., Renner-Muller, I., Kremmer, E., Bauer, C., Wolf, E., Brem, G., Groschup, M. H. & Schatzl, H. M. (2003). Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem 278, 18524–18531.
Goñi, F., Knudsen, E., Schreiber, F., Scholtzova, H., Pankiewicz, J., Carp, R., Meeker, H. C., Rubenstein, R., Brown, D. R. & other authors (2005). Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133, 413–421.[CrossRef][Medline]
Heppner, F. L., Musahl, C., Arrighi, I., Klein, M. A., Rülicke, T., Oesch, B., Zinkernagel, R. M., Kalinke, U. & Aguzzi, A. (2001). Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294, 178–182.
Horiuchi, M. & Caughey, B. (1999). Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 18, 3193–3203.[CrossRef][Medline]
Horiuchi, M., Yamazaki, N., Ikeda, T., Ishiguro, N. & Shinagawa, M. (1995). A cellular form of prion protein (PrPC) exists in many non-neuronal tissues of sheep. J Gen Virol 76, 2583–2587.
Horiuchi, M., Mochizuki, M., Ishiguro, N., Nagasawa, H. & Shinagawa, M. (1997). Epitope mapping of a monoclonal antibody specific to feline panleukopenia virus and mink enteritis virus. J Vet Med Sci 59, 133–136.[CrossRef][Medline]
Kaneko, K., Peretz, D., Pan, K. M., Blochberger, T. C., Wille, H., Gabizon, R., Griffith, O. H., Cohen, F. E., Baldwin, M. A. & Prusiner, S. B. (1995). Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Proc Natl Acad Sci U S A 92, 11160–11164.
Kim, C. L., Umetani, A., Matsui, T., Ishiguro, N., Shinagawa, M. & Horiuchi, M. (2004a). Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. Virology 320, 40–51.[CrossRef][Medline]
Kim, C. L., Karino, A., Ishiguro, N., Shinagawa, M., Sato, M. & Horiuchi, M. (2004b). Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 85, 3473–3482.
Kocisko, D. A., Caughey, W. S., Race, R. E., Roper, G., Caughey, B. & Morrey, J. D. (2006). A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob Agents Chemother 50, 759–761.
Kuwata, K., Nishida, N., Matsumoto, T., Kamatari, Y. O., Hosokawa-Muto, J., Kodama, K., Nakamura, H. K., Kimura, K., Kawasaki, M. & other authors (2007). Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A 104, 11921–11926.
Ladogana, A., Casaccia, P., Ingrosso, L., Cibati, M., Salvatore, M., Xi, Y. G., Masullo, C. & Pocchiari, M. (1992). Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 73, 661–665.
Mallucci, G., Dickinson, A., Linehan, J., Klöhn, P. C., Brandner, S. & Collinge, J. (2003). Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302, 871–874.
Marella, M., Gaggioli, C., Batoz, M., Deckert, M., Tartare-Deckert, S. & Chabry, J. (2005). Pathological prion protein exposure switches on neuronal mitogen-activated protein kinase pathway resulting in microglia recruitment. J Biol Chem 280, 1529–1534.
Morrissey, M. P. & Shakhnovich, E. I. (1999). Evidence for the role of PrPC helix 1 in the hydrophilic seeding of prion aggregates. Proc Natl Acad Sci U S A 96, 11293–11298.
Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. & Weller, R. O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9, 448–452.[CrossRef][Medline]
Orgogozo, J. M., Gilman, S., Dartigues, J. F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L. & other authors (2003). Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46–54.
Paxinos, G. & Franklin, K. B. J. (2001). The Mouse Brain in Stereotaxic Coordinates, 2nd edn. San Diego: Academic Press.
Peretz, D., Williamson, R. A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulm, G., Mehlhorn, I. R., Legname, G., Wormald, M. R. & other authors (2001). Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739–743.[CrossRef][Medline]
Perrier, V., Solassol, J., Crozet, C., Frobert, Y., Mourton-Gilles, C., Grassi, J. & Lehmann, S. (2004). Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 89, 454–463.[Medline]
Priola, S. A., Raines, A. & Caughey, W. S. (2000). Porphyrin and phthalocyanine antiscrapie compounds. Science 287, 1503–1506.
Rainov, N. G., Tsuboi, Y., Krolak-Salmon, P., Vighetto, A. & Doh-Ura, K. (2007). Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin Biol Ther 7, 713–726.[CrossRef][Medline]
Sadowski, M. & Wisniewski, T. (2004). Vaccines for conformational disorders. Expert Rev Vaccines 3, 279–290.[CrossRef][Medline]
Schenk, D. (2002). Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3, 824–828.[Medline]
Schwarz, A., Krätke, O., Burwinkel, M., Riemer, C., Schultz, J., Henklein, P., Bamme, T. & Baier, M. (2003). Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 350, 187–189.[CrossRef][Medline]
Sigurdsson, E. M., Brown, D. R., Daniels, M., Kascsak, R. J., Kascsak, R., Carp, R., Meeker, H. C., Frangione, B. & Wisniewski, T. (2002). Immunization delays the onset of prion disease in mice. Am J Pathol 161, 13–17.
Solforosi, L., Criado, J. R., McGavern, D. B., Wirz, S., Sánchez-Alavez, M., Sugama, S., DeGiorgio, L. A., Volpe, B. T., Wiseman, E. & other authors (2004). Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303, 1514–1516.
Speare, J. O., Rush, T. S., III, Bloom, M. E. & Caughey, B. (2003). The role of helix 1 aspartates and salt bridges in the stability and conversion of prion protein. J Biol Chem 278, 12522–12529.
Todd, N. V., Morrow, J., Doh-ura, K., Dealler, S., O'Hare, S., Farling, P., Duddy, M. & Rainov, N. G. (2005). Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt–Jakob disease. J Infect 50, 394–396.[CrossRef][Medline]
Trevitt, C. R. & Collinge, J. (2006). A systematic review of prion therapeutics in experimental models. Brain 129, 2241–2265.
Uryu, M., Karino, A., Kamihara, Y. & Horiuchi, M. (2007). Characterization of prion susceptibility in Neuro2a mouse neuroblastoma cell subclones. Microbiol Immunol 51, 661–667.[Medline]
White, A. R., Enever, P., Tayebi, M., Mushens, R., Linehan, J., Brandner, S., Anstee, D., Collinge, J. & Hawke, S. (2003). Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80–83.[CrossRef][Medline]
Received 9 November 2007;
accepted 28 February 2008.
This article has been cited by other articles:
|
|
 |
|
  C.-H. Song, O. Honmou, N. Ohsawa, K. Nakamura, H. Hamada, H. Furuoka, R. Hasebe, and M. Horiuchi Effect of Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells on Mice Infected with Prions J. Virol., June 1, 2009; 83(11): 5918 - 5927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Charveriat, M. Reboul, Q. Wang, C. Picoli, N. Lenuzza, A. Montagnac, N. Nhiri, E. Jacquet, F. Gueritte, J.-Y. Lallemand, et al. New inhibitors of prion replication that target the amyloid precursor J. Gen. Virol., May 1, 2009; 90(5): 1294 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Antonyuk, C. R. Trevitt, R. W. Strange, G. S. Jackson, D. Sangar, M. Batchelor, S. Cooper, C. Fraser, S. Jones, T. Georgiou, et al. Crystal structure of human prion protein bound to a therapeutic antibody PNAS, February 24, 2009; 106(8): 2554 - 2558. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
, Mice treated with mAb P2-284; 
, mice treated with mAb 31C6. The presence of PrPSc was confirmed by Western blotting in all experimental-group mice.
